

Financial news for AEGR dated on 2016-11-17: Aegerion Reports JUXTAPID Receives Pricing Authorization In Japan

Financial news for AEGR dated on 2016-11-03: Aegerion Pharmaceuticals Reports Q3 Loss/Share \$0.90 vs Est Loss/Share \$0.84, non-GAAP Loss/Share \$0.37, Sales \$35.4M vs \$28.75M Est

Financial news for AEGR dated on 2016-09-29: Mid-Afternoon Market Update: Dow Falls Over 200 Points; Catabasis Shares Spike Higher

Financial news for AEGR dated on 2016-09-29: 15 Biggest Mid-Day Gainers For Thursday

Financial news for AEGR dated on 2016-09-29: Mid-Day Market Update: Crude Oil Rises Over 2%; Intra-Cellular Therapies Shares Slide

Financial news for AEGR dated on 2016-09-29: Mid-Morning Market Update: Markets Edge Lower; PepsiCo Beats Q3 Expectations

Financial news for AEGR dated on 2016-09-29: 15 Stocks Moving In Thursday's Pre-Market Session

Financial news for AEGR dated on 2016-09-28: Aegerion Pharmaceuticals' JUXTAPID Capsules Approved in Japan for the Treatment of Homozygous Familial Hypercholesterolemia

Financial news for AEGR dated on 2016-09-22: 15 Biggest Mid-Day Gainers For Thursday

Financial news for AEGR dated on 2016-09-14: Broadfin Healthcare Buys 75,000 Shares of Aegerion Pharmaceuticals @\$1.75/Share -Form 4

Financial news for AEGR dated on 2016-08-09: Aegerion Pharmaceuticals Sees FY16 Rev. \$130-\$150M vs. Est. \$134M

Financial news for AEGR dated on 2016-08-09: Aegerion Pharmaceuticals REports Q2 EPS \$(0.72) vs. Est. \$(0.38), Rev. \$44.53M vs. Est. \$35.5M

Financial news for AEGR dated on 2016-07-20: UPDATE: Aegerion Workforce Reduction Seen Saving \$25M-\$35M

Financial news for AEGR dated on 2016-07-20: Aegerion Pharmaceuticals Announces Cost Reduction Plans, Reducing Workforce 13%

Financial news for AEGR dated on 2016-06-22: Hearing Broadfin Will Vote Shares in Favor of Deal Between Aegerion and QLT

Financial news for AEGR dated on 2016-06-15: Mid-Afternoon Market Update: Fed Leaves Rates Unchanged; Bob Evans Farms Shares Drop Following Weak Forecast

Financial news for AEGR dated on 2016-06-15: 10 Biggest Mid-Day Gainers For Wednesday

Financial news for AEGR dated on 2016-06-15: Mid-Day Market Update: Patriot National Climbs Following Offer from Ebix; Carbylan Therapeutics Shares Tumble

Financial news for AEGR dated on 2016-06-15: Mid-Morning Market Update: Markets Open Higher; Aegerion Pharmaceuticals And QLT Agree To Merge

Financial news for AEGR dated on 2016-06-15: Aegerion And QLT Agree To Merge

Financial news for AEGR dated on 2016-06-15: 12 Stocks Moving In Wednesday's Pre-Market Session

Financial news for AEGR dated on 2016-06-15: Aegerion Pharma +25% @\$1.66; QLT +19% Following Resumption of Trade After Merger Announcement

Financial news for AEGR dated on 2016-06-15: Aegerion Pharma, QLT Shares Both Up 20%

Financial news for AEGR dated on 2016-06-15: Shares of QLT, Aegerion Open for Trade; However Not Yet Seeing Updated Indications

Financial news for AEGR dated on 2016-06-15: Shares of Aegerion Pharma, QLT Inc. to Resume Trade at 7:30 a.m. EDT

Financial news for AEGR dated on 2016-06-15: UPDATE: Aegerion, QLT Merger to Happen at 1.0256 Shares of QLT Common

Financial news for AEGR dated on 2016-06-15: Aegerion Pharma, QLT Inc. Announce Merger

Financial news for AEGR dated on 2016-06-15: Aegerion Pharma Shares Halted News

Pending

Financial news for AEGR dated on 2016-05-19: Aegerion Files \$100M Mixed Shelf

Financial news for AEGR dated on 2016-05-17: Mid-Day Market Update: LendingClub Slides Amid Dept. Of Justice Subpoena; Top Image Systems Shares Surge

Financial news for AEGR dated on 2016-05-17: Mid-Morning Market Update: Markets Open Lower; Home Depot Profit Tops Views

Financial news for AEGR dated on 2016-05-17: 10 Stocks Moving In Tuesday's Pre-Market Session

Financial news for AEGR dated on 2016-05-16: UPDATE: Aegerion Cuts FY16 Sales Outlook from \$160M-\$190M to \$130M-\$150M vs \$175M Est.

Financial news for AEGR dated on 2016-05-16: Aegerion Cuts FY16 Sales Outlook

Financial news for AEGR dated on 2016-05-16: Aegerion Pharma Reports Q1 EPS \$(2.22) vs \$(0.05) in Same Qtr. Last Year, Sales \$35.7M

Financial news for AEGR dated on 2016-05-16: Earnings Scheduled For May 16, 2016

Financial news for AEGR dated on 2016-05-12: Aegerion Pharmaceuticals Reaches Agreement With DOJ and SEC Regarding JUXTAPID Settlement Totaling \$40M

Financial news for AEGR dated on 2016-05-11: Aegerion Pharmaceuticals Files for Non-Timely 10-Q

Financial news for AEGR dated on 2016-04-11: Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

Financial news for AEGR dated on 2016-03-16: Mid-Afternoon Market Update: Dow Gains 125 Points; Crude Oil Up 5%

Financial news for AEGR dated on 2016-03-07: Armistice Capital, LLC Reports 5.2% Passive Stake in Aegerion Pharmaceuticals in 13G

Financial news for AEGR dated on 2016-02-25: Aegerion Sees FY16 Global Sales \$160M-\$190M vs \$235.5M Est.

Financial news for AEGR dated on 2016-02-25: Aegerion Pharma Reports Q4 EPS \$(1.26) vs \$(0.89) Est., Sales \$49.003M vs \$47.7M Est.

Financial news for AEGR dated on 2016-02-16: Paulson & Co New Stakes: Abbvie, Aegerion Pharma, Biogen, ETSY, Insmmed, LAM Research, Laboratory Corp, Novagold, Priceline, Rigel Pharma, Lyon Williams Homes

Financial news for AEGR dated on 2016-02-12: Bank of America Downgrades Aegerion Pharmaceuticals to Underperform

Financial news for AEGR dated on 2016-02-11: Aegerion Pharma. Reports 25% Reduction In Workforce

Financial news for AEGR dated on 2016-02-03: Aegerion Pharma Says Greg Perry To Be Principal Financial Officer

Financial news for AEGR dated on 2016-01-21: Mid-Morning Market Update: Markets Drop; Verizon Profit Tops Estimates

Financial news for AEGR dated on 2016-01-11: Aegerion Pharma Sees Q4 Product Sales \$37.5M to \$39.5M

Financial news for AEGR dated on 2016-01-07: Aegerion Pharmaceuticals Names Mary Szela CEO

Financial news for AEGR dated on 2015-12-21: Benzinga's Top Upgrades

Financial news for AEGR dated on 2015-12-21: Guggenheim Securities Upgrades Aegerion Pharmaceuticals to Buy, Raises PT to \$13.00

Financial news for AEGR dated on 2015-12-03: Option Alert: AEGR Jan16 12.5 Calls Sweep: 500 @ ASK \$0.80: 500 traded vs 113 OI: \$10.31 Ref

Financial news for AEGR dated on 2015-11-20: JUXTAPID Capsules Available on the Regie de l'Assurance Maladie du Quebec for the Treatment of Homozygous Familial Hypercholesterolemia

Financial news for AEGR dated on 2015-11-10: Aegerion Pharmaceuticals Announces

Results From First Year of LOWER Study at AHA Scientific Sessions 2015

Financial news for AEGR dated on 2015-11-10: Option Alert: \$AEGR Mar \$17.5 Call; 5000 Contracts @\$1.05

Financial news for AEGR dated on 2015-11-09: Aegerion Pharma Reported Q3 Adj. EPS \$0.20

Financial news for AEGR dated on 2015-11-05: Aegerion Pharmaceuticals Postpones Q3 Conference Call To Monday 5pm ET, To Provide Business Update & Discuss Q3 Financial, Operating Results

Financial news for AEGR dated on 2015-10-19: Cowen: In Biotech Earnings We Trust

Financial news for AEGR dated on 2015-10-07: Aegerion Pharmaceuticals Grants 56.923K Stock Options Under Inducement Program, Exercise Price Of \$13.19

Financial news for AEGR dated on 2015-10-06: Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

Financial news for AEGR dated on 2015-09-14: Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

Financial news for AEGR dated on 2015-08-05: Aegerion Pharma Reports Q2 Loss \$0.37 Vs Est Loss \$0.28, Sales \$57.1M Vs Est \$58.98M

Financial news for AEGR dated on 2015-07-28: Benzinga's Top Upgrades

Financial news for AEGR dated on 2015-07-28: Jefferies Upgrades Aegerion Pharma To Buy, Sees Positively Skewed Risk/Reward

Financial news for AEGR dated on 2015-07-28: Jefferies discusses Aegerion upgrade, sees "management change potentially leading to restored investor confidence...concerns largely priced in."

Financial news for AEGR dated on 2015-07-28: Jefferies Upgrades Aegerion Pharmaceuticals to Buy, Maintains \$26.00 PT

Financial news for AEGR dated on 2015-07-27: Aegerion Pharma Reports Marc Beer To Resign As CEO And Board Member, Names Drexel Smith Interim CEO; Craig Fraser Steps Down As COO

Financial news for AEGR dated on 2015-07-13: Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program, 71K Shares At \$18.83

Financial news for AEGR dated on 2015-07-06: Benzinga's Top Downgrades

Financial news for AEGR dated on 2015-07-06: Guggenheim Securities Downgrades Aegerion Pharmaceuticals To Sell

Financial news for AEGR dated on 2015-07-06: Guggenheim Securities Downgrades Aegerion Pharmaceuticals to Sell

Financial news for AEGR dated on 2015-06-25: Aegerion Pharmaceuticals Appoints Gregory Perry as CFO

Financial news for AEGR dated on 2015-06-16: Aegerion Pharmaceuticals Announces Key Additions to Medical Affairs and Drug Safety

Financial news for AEGR dated on 2015-05-29: 13G Filing: Stonepine Capital Reports 5.2% Passive Stake In Aegerion Pharmaceuticals

Financial news for AEGR dated on 2015-05-14: Aegerion Pharma Announces CFO Mark Fitzpatrick Resigns

Financial news for AEGR dated on 2015-05-04: Aegerion Pharma Reports Q1 EPS \$0.06 vs. Est. \$(0.26), Rev. \$59.38M vs. Est. \$52.29M; EPS Estimate May Not Compare

Financial news for AEGR dated on 2015-03-30: Aegerion Pharma, Sarissa Capital Reach Board Member Agreement

Financial news for AEGR dated on 2015-03-30: Aegerion Pharma Reports Deal with Sarissa Capital Mgmt

Financial news for AEGR dated on 2015-03-10: Aegerion Pharma Grants Stock Options; Press Release Below

Financial news for AEGR dated on 2015-02-05: Activist Discloses 5.7% Stake In Aegerion Pharmaceuticals

Financial news for AEGR dated on 2015-02-05: 13D: Sarissa Capital Reports 5.76% Stake In Aegerion Pharma

Financial news for AEGR dated on 2015-02-05: 13D Out on Aegerion

Financial news for AEGR dated on 2015-02-05: Aegerion Pharma Shares Spike Higher

Financial news for AEGR dated on 2015-01-15: 10 Biotech Stories You Might've Missed This Week

Financial news for AEGR dated on 2015-01-14: Report: Holders Push For Sale At Aegerion Pharmaceuticals

Financial news for AEGR dated on 2015-01-14: UPDATE: Aegerion Pharmaceuticals Rise 12% on Report Investors Want CEO Out, Co to be Sold

Financial news for AEGR dated on 2015-01-14: Reuters Reports Several Top 10 Investors Urging Aegerion Pharmaceuticals to Oust CEO, Consider Sale, According to Sources

Financial news for AEGR dated on 2015-01-14: Hearing Unconfirmed Activist Activity in Aegerion

Financial news for AEGR dated on 2015-01-14: Aegerion Spikes Higher

Financial news for AEGR dated on 2015-01-13: Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

Financial news for AEGR dated on 2015-01-12: Big Short Interest On These 5 Biotech Stocks

Financial news for AEGR dated on 2015-01-12: Morning Market Gainers

Financial news for AEGR dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for AEGR dated on 2015-01-12: UPDATE: Aegerion Expecting FY15 Global Net Product Sales Growth in 30-50% Range

Financial news for AEGR dated on 2015-01-12: Aegerion Pharmaceuticals Sees Q4 Sales \$49.30M-51.30M

Financial news for AEGR dated on 2015-01-05: Option Alert: Aegerion Pharmaceuticals Jan \$20 Call; 1,850 Contracts Traded vs 683 OI; Currently \$22.51

Financial news for AEGR dated on 2014-11-06: Aegerion Acquires Myalept from AstraZeneca for \$325M Upfront Payment

Financial news for AEGR dated on 2014-11-03: Meet The Biopharma Stock That Lost 34% Last Week

Financial news for AEGR dated on 2014-10-31: Midday Losers From October 31: Aegerion Pharmaceuticals, Bottomline Technologies, Digital Globe

Financial news for AEGR dated on 2014-10-31: Mid-Day Market Update: GoPro Jumps On Upbeat Results; Tempur Sealy Shares Dip

Financial news for AEGR dated on 2014-10-31: Mid-Morning Market Update: Markets Open Higher; Clorox Earnings Top Street View

Financial news for AEGR dated on 2014-10-31: Morning Market Losers

Financial news for AEGR dated on 2014-10-31: Needham Downgrades Aegerion Pharmaceuticals, Inc. to Hold

Financial news for AEGR dated on 2014-10-31: Bank of America Downgrades Aegerion Pharmaceuticals, Inc. to Underperform

Financial news for AEGR dated on 2014-10-31: Benzinga's Top Downgrades

Financial news for AEGR dated on 2014-10-31: Benzinga's Top #PreMarket Losers

Financial news for AEGR dated on 2014-10-31: Jefferies Downgrades Aegerion Pharmaceuticals To Hold

Financial news for AEGR dated on 2014-10-31: Deutsche Bank Downgrades Aegerion Pharmaceuticals, Inc. to Hold, Lowers Pt to \$26.00

Financial news for AEGR dated on 2014-10-31: JP Morgan Downgrades Aegerion

Pharmaceuticals, Inc. to Neutral, Lowers PT to \$43.00

Financial news for AEGR dated on 2014-10-31: Jefferies Downgrades Aegerion Pharmaceuticals, Inc. to Hold, Lowers PT to \$24.00

Financial news for AEGR dated on 2014-10-30: Aegerion Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.22) vs \$(0.14) Est; Revenue of \$43.70M vs \$48.64M Est

Financial news for AEGR dated on 2014-10-20: Bank Of America Q3 Small & Mid-Cap Biotech Preview

Financial news for AEGR dated on 2014-10-14: 13G Filing from Point72 on Aegerion Pharma Shows Raised Stake from 3.13% as of Jun. 30 to 5.2%

Financial news for AEGR dated on 2014-10-08: Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

Financial news for AEGR dated on 2014-09-09: Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

Financial news for AEGR dated on 2014-08-27: Aegerion Pharmaceuticals Announces Resolution Of Warning Letter for JUXTAPID (lomitapide) Capsules

Financial news for AEGR dated on 2014-08-27: Aegerion Pharmaceuticals Announces Resolution of Warning Letter for JUXTAPID Capsules

Financial news for AEGR dated on 2014-08-20: Aegerion Pharmaceuticals CFO Fitzpatrick Buys 1,150 Shares @\$30.64/Share -Form 4

Financial news for AEGR dated on 2014-08-11: Scopia Capital Management Reports 14.20% Passive Stake In Aegerion Pharmaceuticals as of August 8

Financial news for AEGR dated on 2014-08-11: Markets Open Higher; Priceline Issues Downbeat Profit Forecast

Financial news for AEGR dated on 2014-08-11: US Stock Futures Signal Higher Start On Wall Street

Financial news for AEGR dated on 2014-08-11: Aegerion Pharmaceuticals to Offer \$250M of Convertible Notes

Financial news for AEGR dated on 2014-07-31: Aegerion Pharmaceuticals CEO Beer Buys 10,000 Shares @\$33.65/Share -Form 4

Financial news for AEGR dated on 2014-07-30: The FED Continues To Taper; Indices Rebound Slightly

Financial news for AEGR dated on 2014-07-30: Twitter Jumps On Upbeat Results; DreamWorks Shares Slide

Financial news for AEGR dated on 2014-07-30: Markets Mixed; Sprint Posts Profit

Financial news for AEGR dated on 2014-07-30: Benzinga's Volume Movers

Financial news for AEGR dated on 2014-07-30: Morning Market Movers

Financial news for AEGR dated on 2014-07-30: Aegerion Pharma Announces Craig Fraser COO

Financial news for AEGR dated on 2014-07-30: Benzinga's Top #PreMarket Gainers

Financial news for AEGR dated on 2014-07-29: Aegerion Pharma Announces Revenue of \$36M, EPS of \$0.04 Versus \$0.42 in 2013

Financial news for AEGR dated on 2014-07-18: Stocks Hitting 52-Week Lows

Financial news for AEGR dated on 2014-07-18: Stocks Hitting 52-Week Lows

Financial news for AEGR dated on 2014-07-09: 5-Star Biotech Stock Watch: Aegerion Pharmaceuticals

Financial news for AEGR dated on 2014-07-09: Stocks Hitting 52-Week Lows

Financial news for AEGR dated on 2014-06-04: Aegerion Pharmaceuticals Shares Move to High on Volume; CEO Beer Reported Additional 10,000 Share Buy Earlier

Financial news for AEGR dated on 2014-05-27: Market Wrap For May 27: S&P 500 Closes At New Record High After Holiday Weekend

Financial news for AEGR dated on 2014-05-27: Aegerion Pharmaceuticals CEO Beer Buys 10,000 Shares @\$31.59/Share -Form 4

Financial news for AEGR dated on 2014-05-27: Benzinga's Top Initiations

Financial news for AEGR dated on 2014-05-27: Goldman Sachs Initiates Coverage on Aegerion Pharmaceuticals, Inc. at Sell, Announces \$27.00 PT

Financial news for AEGR dated on 2014-05-08: Aegerion Pharmaceuticals CEO Beer Buys 30,000 Shares @\$35.31/Share -Form 4

Financial news for AEGR dated on 2014-05-07: Earlier Cowen & Company Downgraded Aegerion Pharmaceuticals to Market Perform, Lowered PT to \$36.00 While Shares Drop On Earnings

Financial news for AEGR dated on 2014-05-07: Morning Market Losers

Financial news for AEGR dated on 2014-05-06: Aegerion Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.25); Revenue of \$27.0M

Financial news for AEGR dated on 2014-04-09: UPDATE: Aegerion Pharma Commences Phase 3 Clinical Trial in Japan, Will Evaluate Lomitapide for Treatment of HoFH

Financial news for AEGR dated on 2014-04-09: Aegerion Pharma Commences Phase 3 Clinical Trial in Japan, Will Evaluate Lomitapide for Treatment of HoFH

Financial news for AEGR dated on 2014-02-26: Aegerion Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.14) vs \$(0.30) Est; Revenue of \$24.50M vs \$24.51M Est

Financial news for AEGR dated on 2014-02-11: Aegerion Pharma Says JUXTAPID Caps Approved for HoFH in Canada

Financial news for AEGR dated on 2014-01-20: Aegerion's JUXTAPID Capsules Approved in Mexico for Treatment of Homozygous Familial Hypercholesterolemia

Financial news for AEGR dated on 2014-01-09: Aegerion Says Received Subpoena from DoJ, Reports Prelim. 2013 Product Sales \$48-49M, Prelim. '14 Product Sales \$190-210M

Financial news for AEGR dated on 2013-11-25: Option Alert: Aegerion Pharmaceuticals January 75 Call; 2,000 Contract Trade at Ask @\$5.00; Currently \$68.19

Financial news for AEGR dated on 2013-11-21: FBR Capital Initiates Coverage on Aegerion Pharmaceuticals, Inc. at Outperform, Announces \$111.00 PT

Financial news for AEGR dated on 2013-11-19: Leerink Swann Reiterates on Aegerion Pharmaceuticals as Weakness is Overdone

Financial news for AEGR dated on 2013-11-19: Canaccord Genuity Reiterates on Aegerion Pharmaceuticals as Selling is Overdone

Financial news for AEGR dated on 2013-11-19: Canaccord's Richter Suggesting Buying the Dip in Shares of Aegerion, Believes Selling Pressure Overdone

Financial news for AEGR dated on 2013-11-18: Aegerion Pharmaceuticals Presents Data From Phase 3 Extension Study of JUXTAPID(TM) (lomitapide) Capsules in Homozygous Familial Hypercholesterolemia (HoFH) at AHA Scientific Sessions

Financial news for AEGR dated on 2013-11-13: UPDATE: Deutsche Bank Reiterates on Aegerion Pharmaceuticals Following Company Analyst Day

Financial news for AEGR dated on 2013-11-13: Deutsche Bank Maintains Buy on Aegerion Pharmaceuticals, Inc., Raises PT to \$115.00

Financial news for AEGR dated on 2013-11-08: Market Wrap For November 8: Markets Erase Thursday's Losses; Dow Companies Dominate Headlines

Financial news for AEGR dated on 2013-11-08: UPDATE: Aegerion Shares Now Selling Off on FDA Warning Letter

Financial news for AEGR dated on 2013-11-08: Traders Not Responding to News of Warning Letter from FDA to Aegerion Pharma Related to Comments Made on 'Fast Money'

Financial news for AEGR dated on 2013-10-31: Jefferies Maintains Buy on Aegerion Pharmaceuticals, Inc., Raises PT to \$102.00

Financial news for AEGR dated on 2013-10-30: Aegerion Pharma Shares Down Nearly 8% Amid Q3 Results, Leerink's Schwartz Says Buy the Dip

Financial news for AEGR dated on 2013-10-29: Kingdon on Aegerion: Citing Juxtapid,

Orphan Drug Designation, Patient Base of 15K, Says Sales of \$1.25B, \$25 in EPS Possible

Financial news for AEGR dated on 2013-10-29: Kingdon Recommending Aegerion Pharma at Invest for Kids Conference

Financial news for AEGR dated on 2013-10-09: Option Alert: Activity in Aegerion October 80, November 85, 100 Calls; Currently \$76.27

Financial news for AEGR dated on 2013-09-18: Hearing Deutsche Bank Defending Aegerion Pharmaceuticals

Financial news for AEGR dated on 2013-09-09: Aegerion Pharma's Lomitapide Wins Orphan Drug Status in Japan

Financial news for AEGR dated on 2013-08-01: Aegerion Wins European Approval for Lojuxta for HOFH

Financial news for AEGR dated on 2013-07-31: Jefferies Maintains Buy on Aegerion Pharmaceuticals, Inc., Raises PT to \$92.00

Financial news for AEGR dated on 2013-07-30: Aegerion Pharmaceuticals, Inc. Raises FY2013 Sales Guidance from \$15.0M-25.0M to \$30.0M-35.0M vs \$31.20M Est

Financial news for AEGR dated on 2013-07-30: Aegerion Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.66) vs \$(0.62) Est; Revenue of \$6.50M vs \$4.27M Est

Financial news for AEGR dated on 2013-07-17: Some Highlights from 'Delivering Alpha' Conference: Chanos, Paulson, Cooperman, Kingdon, Hohn

Financial news for AEGR dated on 2013-07-17: Kingdon: 'Aegerion Patient Size Could be 15,000'

Financial news for AEGR dated on 2013-07-17: Kingdon Likes Aegerion

Financial news for AEGR dated on 2013-07-16: Option Alert: Unusual Activity in Aegerion Pharmaceuticals July 60, August 70, September 85, September 110 Calls; Currently \$76.32

Financial news for AEGR dated on 2013-06-19: Five Stocks To Protect Your Portfolio From A Falling Dow

Financial news for AEGR dated on 2013-06-07: UPDATE: Bank of America Raises PO on Aegerion Pharmaceuticals on Positive Updates

Financial news for AEGR dated on 2013-06-07: Bank of America Maintains Buy on Aegerion Pharmaceuticals, Inc., Raises PO to \$100.00

Financial news for AEGR dated on 2013-06-05: UPDATE: Aegerion CEO Beer Says Justapide Will Be Given to Patients Without Insurance, Said Euro Regulator Response Has Been Positive

Financial news for AEGR dated on 2013-06-05: Watch Shares of Aegerion Pharma Here as CEO Beer Currently Speaking on CNBC

Financial news for AEGR dated on 2013-06-05: UPDATE: Jefferies Raises PT on Aegerion Pharmaceuticals Following Global Healthcare Conference

Financial news for AEGR dated on 2013-06-05: Jefferies Maintains Buy on Aegerion Pharmaceuticals, Inc., Raises PT to \$82.00

Financial news for AEGR dated on 2013-06-03: Aegerion Pharma Price Target Boosted from \$65 to \$98 at Leerink Swann, Maintains Outperform

Financial news for AEGR dated on 2013-05-31: Aegerion Receives Positive European CHMP Opinion for LOJUXTA for Homozygous Familial Hypercholesterolemia

Financial news for AEGR dated on 2013-05-31: Aegerion Pharma Wins Positive European CHMP Opinion for Lomitapide

Financial news for AEGR dated on 2013-05-29: Market Wrap for Wednesday, May 29: Stocks Fall on Profit Taking After Big Rally

Financial news for AEGR dated on 2013-05-29: Mid-Afternoon Market Update: Markets Remain Down as Aegerion Pharma Rises On J.P. Morgan Price Target

Financial news for AEGR dated on 2013-05-29: Afternoon Market Gainers

Financial news for AEGR dated on 2013-05-29: Aegerion Pharma Target Raised from \$54

to \$90 at Canaccord, Maintains Buy

Financial news for AEGR dated on 2013-05-29: UPDATE: Canaccord Genuity Raises PT on Aegerion Pharmaceuticals Following Tracking Survey Results

Financial news for AEGR dated on 2013-05-29: UPDATE: J.P. Morgan Raises PT on Aegerion Pharmaceuticals in Continuing Doc Rounds Series

Financial news for AEGR dated on 2013-05-29: Morning Market Movers

Financial news for AEGR dated on 2013-05-16: Market Wrap for Thursday, May 16: A Small Pullback For U.S. Stocks as Economic Data Disappoints

Financial news for AEGR dated on 2013-05-16: Mid-Afternoon Market Update: Optimer Falls as Halozyme Rockets Upwards

Financial news for AEGR dated on 2013-05-16: Aegerion Pharmaceuticals Spokesperson Says Company has No Immediate Plan to Raise Funds Through Secondary Offering

Financial news for AEGR dated on 2013-05-16: Aegerion Pharmaceuticals Strength Most Likely Due to Company Presentation Given by CEO Mark Beer in Las Vegas on Wednesday

Financial news for AEGR dated on 2013-05-16: Mid-Day Market Update: US Stocks Fluctuate, Cisco Systems Up on Better-than-Expected Earnings

Financial news for AEGR dated on 2013-04-30: Aegerion Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.64) vs \$(0.74) Est

Financial news for AEGR dated on 2013-04-19: Stocks to Watch for April 19, 2013

Financial news for AEGR dated on 2013-04-04: Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

Financial news for AEGR dated on 2013-04-03: Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

Financial news for AEGR dated on 2013-03-28: UPDATE: Deutsche Bank Raises PT on Aegerion Pharmaceuticals on Dropout Assumptions

Financial news for AEGR dated on 2013-03-27: Deutsche Bank Maintains Buy on Aegerion Pharmaceuticals, Inc., Raises PT to \$52.00

Financial news for AEGR dated on 2013-03-11: Bank of America Reiterates Buy Rating on Aegerion Pharmaceuticals Following ACC Meeting

Financial news for AEGR dated on 2013-03-07: UPDATE: Canaccord Genuity Raises PT to \$44 on Aegerion Pharmaceuticals on Encouraging Sales Data

Financial news for AEGR dated on 2013-03-07: UPDATE: JP Morgan Raises PT to \$39 on Aegerion Pharmaceuticals on Encouraging Juxtapid Sales

Financial news for AEGR dated on 2013-03-07: UPDATE: Bank of America Raises PO to \$42 on Aegerion Pharmaceuticals; Juxtapid Launch Solid

Financial news for AEGR dated on 2013-03-07: JP Morgan Maintains Overweight on Aegerion Pharmaceuticals, Inc., Raises PT to \$39.00

Financial news for AEGR dated on 2013-03-07: Canaccord Genuity Maintains Buy on Aegerion Pharmaceuticals, Inc., Raises PT to \$44.00

Financial news for AEGR dated on 2013-03-06: Bank of America Maintains Buy on Aegerion Pharmaceuticals, Inc., Raises PT to \$42.00

Financial news for AEGR dated on 2013-03-06: UPDATE: Jefferies Raises PT to \$40 on Aegerion Pharmaceuticals on Strong Juxtapid Start

Financial news for AEGR dated on 2013-03-06: Jefferies Maintains Buy on Aegerion Pharmaceuticals, Inc., Raises PT to \$40.00

Financial news for AEGR dated on 2013-03-06: UPDATE: Deutsche Bank Raises PT on Aegerion Pharmaceuticals on Strong Juxtapid Uptake

Financial news for AEGR dated on 2013-03-06: Aegerion Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.86) vs \$(0.63) Est

Financial news for AEGR dated on 2013-03-06: Earnings Scheduled For March 6, 2013

Financial news for AEGR dated on 2013-03-05: UPDATE: Bank of America Initiates Aegerion Pharmaceuticals at Buy on Juxtapid Launch Upside

Financial news for AEGR dated on 2013-03-05: Bank of America Initiates Coverage on Aegerion Pharmaceuticals, Inc. at Buy, Announces \$39.00 PO

Financial news for AEGR dated on 2013-02-11: Lazard Capital Markets Upgrades Aegerion Pharmaceuticals, Inc. to Buy

Financial news for AEGR dated on 2013-01-30: Isis and Sanofi's Drug OK'd to Treat Inherited Cholesterol Disease

Financial news for AEGR dated on 2013-01-11: Mid-Morning Market Update: Markets Heading Down, Dendreon Rockets Upwards

Financial news for AEGR dated on 2013-01-11: Aegerion Pharma Prices 2.7M Shares to \$26.64/Share

Financial news for AEGR dated on 2013-01-10: Aegerion Pharma Announces Proposed Public Offering of Stock

Financial news for AEGR dated on 2013-01-09: UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on Aegerion Pharmaceuticals

Financial news for AEGR dated on 2013-01-09: Canaccord Genuity Maintains Buy on Aegerion Pharmaceuticals, Inc., Raises PT to \$36.00

Financial news for AEGR dated on 2013-01-08: From Earlier: Craig-Hallum Initiates Coverage on Aegerion Pharmaceuticals, Inc. at Buy, Announces \$30.00 PT

Financial news for AEGR dated on 2013-01-07: Aegerion Pharma Offers Updates Ahead of US Launch of JUXTAPID Caps

Financial news for AEGR dated on 2013-01-07: Aegerion Pharmaceuticals Reports Objectives for 2013 Prior to US Launch of JUXTAPID Capsules

Financial news for AEGR dated on 2013-01-04: Aegerion Pharmaceuticals Grants Stock Options to Purchase 55K Shares

Financial news for AEGR dated on 2013-01-02: Janney Capital Initiates Coverage on Aegerion Pharmaceuticals, Inc. at Buy, Announces \$30.00 PT

Financial news for AEGR dated on 2012-12-27: UPDATE: Jefferies Raises PT to \$29 on Aegerion Pharmaceuticals on Juxtapid Approval Outlook

Financial news for AEGR dated on 2012-12-27: Jefferies Maintains Buy on Aegerion Pharmaceuticals, Inc., Raises PT to \$29.00

Financial news for AEGR dated on 2012-12-26: Canaccord Genuity Reiterates Buy Rating, \$27 PT on Aegerion Pharmaceuticals

Financial news for AEGR dated on 2012-12-26: Stocks To Watch For December 26, 2012

Financial news for AEGR dated on 2012-12-24: Aegerion Pharmaceuticals Wins Approval for Cholesterol Drug

Financial news for AEGR dated on 2012-12-24: UPDATE: J.P. Morgan Reiterates Overweight Rating, Raises PT on Aegerion Pharmaceuticals

Financial news for AEGR dated on 2012-12-24: JP Morgan Maintains Overweight on Aegerion Pharmaceuticals, Inc., Raises PT to \$30.00

Financial news for AEGR dated on 2012-12-24: Aegerion Pharmaceuticals Resumes Trading, Up 1.5% Pre-Market

Financial news for AEGR dated on 2012-12-24: FDA Approves Aegerion's' JUXTAPID Capsules for Homozygous Familial Hypercholesterolemia

Financial news for AEGR dated on 2012-12-21: From Earlier: Cowen & Company Initiates Coverage on Aegerion Pharmaceuticals, Inc. to Outperform

Financial news for AEGR dated on 2012-12-08: Benzinga's M&A Chatter for Friday December 7, 2012

Financial news for AEGR dated on 2012-12-07: JP Morgan Shows 10% Passive Stake in Aegerion Pharma

Financial news for AEGR dated on 2012-12-07: Hearing Deal Reporter Says Aegerion a Takeover Target

Financial news for AEGR dated on 2012-12-06: Aegerion Pharma Reserves Shares for

Inducement Stock Options

Financial news for AEGR dated on 2012-11-28: Aegerion Pharmaceuticals Issued Patent by European Patent Office

Financial news for AEGR dated on 2012-10-24: UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Aegerion Pharmaceuticals

Financial news for AEGR dated on 2012-10-24: Jefferies & Company Maintains Aegerion Pharmaceuticals at Buy, Raises PT from \$22 to \$24

Financial news for AEGR dated on 2012-10-18: Aegerion Pharmaceuticals Spikes Higher

Financial news for AEGR dated on 2012-10-18: Jefferies & Company Maintains Aegerion Pharmaceuticals at Buy, Raises PT from \$20 to \$22

Financial news for AEGR dated on 2012-10-18: Deutsche Bank Maintains Aegerion Pharmaceuticals at Buy, Raises PT from \$19 to \$30

Financial news for AEGR dated on 2012-10-17: FDA EMDAC Recommends Approval of Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

Financial news for AEGR dated on 2012-10-17: FDA Advisers Vote 13-2 that Aegerion Data Sufficient For Approval

Financial news for AEGR dated on 2012-10-17: Benzinga Mid-Afternoon Market Update

Financial news for AEGR dated on 2012-10-17: Benzinga Mid-Day Market Update

Financial news for AEGR dated on 2012-10-17: Benzinga Mid-Morning Market Update

Financial news for AEGR dated on 2012-10-17: UPDATE: Aegerion Pharmaceuticals Halted, FDA to Consider NDA for Lomitapide

Financial news for AEGR dated on 2012-10-17: Aegerion Pharmaceuticals Halted; Pending News

Financial news for AEGR dated on 2012-10-16: Benzinga Mid-Afternoon Market Update

Financial news for AEGR dated on 2012-10-16: Benzinga Mid-Morning Market Update

Financial news for AEGR dated on 2012-10-15: Benzinga Mid-Afternoon Market Update

Financial news for AEGR dated on 2012-10-15: Benzinga Mid-Day Market Update

Financial news for AEGR dated on 2012-10-15: Benzinga Mid-Morning Market Update

Financial news for AEGR dated on 2012-10-12: Aegerion Pharmaceuticals Sent Investors Email Invitations to October 23 Cocktail Party at Waldorf Astoria -Adam F Tweet

Financial news for AEGR dated on 2012-10-09: Options Alert - Aegerion Pharmaceuticals

Financial news for AEGR dated on 2012-10-03: UPDATE: J.P. Morgan Initiates Coverage on Aegerion Pharmaceuticals with Overweight Rating, \$22 PT

Financial news for AEGR dated on 2012-10-03: JP Morgan Initiates Coverage on Aegerion Pharmaceuticals at Overweight, Announces PT of \$22

Financial news for AEGR dated on 2012-08-14: Aegerion Pharmaceuticals Announces Date of FDA Advisory Committee Review of Lomitapide NDA

Financial news for AEGR dated on 2012-08-08: Aegerion Pharmaceuticals Reports Q2 EPS \$-0.63 vs \$-0.51 Est

Financial news for AEGR dated on 2012-07-02: Isis Pharmaceuticals Heavy Put Volume May be Attributed to Seeking Alpha Article on Company's Cholesterol Drug

Financial news for AEGR dated on 2012-06-29: ThinkEquity Initiates Coverage on Aegerion Pharmaceuticals at Buy

Financial news for AEGR dated on 2012-06-15: Social Media Outlook for Friday June 15 (IGT, AEGR, AOL, GS)

Financial news for AEGR dated on 2012-06-14: Benzinga's Top Pre-Market Losers

Financial news for AEGR dated on 2012-06-14: Aegerion Pharmaceuticals Prices 3.4M Share Public Offering of Common Stock at \$14.75/Share

Financial news for AEGR dated on 2012-06-14: Benzinga's Top Pre-Market Losers

Financial news for AEGR dated on 2012-06-14: Stocks To Watch For June 14

Financial news for AEGR dated on 2012-06-13: Aegerion Pharmaceuticals Announces Proposed Public Offering of Common Stock; No Amount Given

Financial news for AEGR dated on 2012-05-22: Needham Initiates Coverage on Aegerion Pharmaceuticals at Buy, Announces PT of \$24

Financial news for AEGR dated on 2012-03-26: Canaccord Initiates Coverage on Aegerion Pharmaceuticals at Buy, Announces PT of \$27

Financial news for AEGR dated on 2012-03-08: Aegerion Pharmaceuticals Comments on Standard Review Classification for Lomitapide NDA

Financial news for AEGR dated on 2012-03-06: Earnings Scheduled For March 6

Financial news for AEGR dated on 2012-03-05: Financial Breakfast: Morning News Summary for March 5, 2012

Financial news for AEGR dated on 2012-03-05: Aegerion Pharmaceuticals Submits Marketing Applications for Lomitapide in U.S. and EU

Financial news for AEGR dated on 2012-01-06: Aegerion Pharmaceuticals Announces Lomitapide 78-Week Phase III Clinical Data Consistent With Earlier Results

Financial news for AEGR dated on 2011-11-09: Deutsche Bank Initiates Aegerion Pharmaceuticals at Buy, \$19 PT

Financial news for AEGR dated on 2011-10-10: Jefferies Initiates Coverage on Aegerion Pharmaceuticals with a Buy Rating

Financial news for AEGR dated on 2011-10-10: Jefferies Initiates Aegerion Pharmaceuticals at Buy, \$20 PT

Financial news for AEGR dated on 2011-09-28: European Regulators Confirm Filing Strategy for Drug Candidate, Lomitapide

Financial news for AEGR dated on 2011-07-27: Aegerion Pharma Reports Q2 EPS of \$(0.49) vs. \$(0.40) Est

Financial news for AEGR dated on 2011-07-22: Aegerion Pharmaceuticals Appoints Dr. Mark Sumeray as Chief Medical Officer

Financial news for AEGR dated on 2011-07-21: Aegerion Pharmaceuticals Announces Appointment of Paul G. Thomas to Its Board of Directors

Financial news for AEGR dated on 2011-06-29: Aegerion Pharmaceuticals: CEO Beer Buys 64,516 Shares at \$15.50, Worth Over \$999K

Financial news for AEGR dated on 2011-06-28: Global Hunter Initiates Coverage of Aegerion Pharmaceuticals with Buy and PT of \$23

Financial news for AEGR dated on 2011-06-24: A Peek Into The Market Before The Trading Starts

Financial news for AEGR dated on 2011-06-24: Aegerion Pharmaceuticals Announces Public Offering Of 4,250,000 Shares At \$15.50 Per Share

Financial news for AEGR dated on 2011-06-16: UPDATE: Aegerion Pharmaceuticals Files Registration Statement for Proposed Offering of 4.25M Shares

Financial news for AEGR dated on 2011-06-16: UPDATE: Aegerion will Use the Proceeds for the Lomitapide Trial and Studies

Financial news for AEGR dated on 2011-06-16: Aegerion Pharma Files 3.25M-Share Stock Shelf Offering -Dow Jones

Financial news for AEGR dated on 2011-06-16: Aegerion Pharmaceuticals Holds Pre-NDA Meeting With FDA for Investigational Lomitapide and is on Track for NDA Submission

Financial news for AEGR dated on 2011-04-27: Aegerion Pharmaceuticals Appoints Mark J. Fitzpatrick as Chief Financial Officer (AEGR)

Financial news for AEGR dated on 2011-04-14: Aegerion Pharmaceuticals Acknowledges the National Lipid Association's Revised Guidelines for the Treatment of Familial Hypercholesterolemia

Financial news for AEGR dated on 2011-03-28: NASDAQ Stocks Hitting 52-Week Highs

(JOSB, AEGR, KNXA, DRCO)